Aeterna Zentaris Regains Compliance with NASDAQ $1.00 Minimum Bid Price Rule

 Aeterna Zentaris Regains Compliance with NASDAQ $1.00 Minimum Bid Price Rule

PR Newswire

QUÉBEC CITY, Oct. 22, 2012

QUÉBEC CITY, Oct. 22, 2012 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS)
(TSX:AEZ) (the"Company") today announced that on October 19,  2012, NASDAQ
notified the Company that it has regained compliance with Rule 5450(a)(1),
which requires a minimum bid price of $1.00 for continued listing on the
NASDAQ Global Market.

Commenting on the announcement, Juergen Engel, Ph.D., President and Chief
Executive Officer, stated: "We are pleased that we have been able to regain
compliance with NASDAQ's minimum bid price rule, which is important in
maintaining liquidity in the trading of our common shares. We will continue to
pursue our objective of maximizing shareholder value with a goal of becoming a
specialty oncology and endocrinology company developing drugs for indications
with various unmet medical needs."

About Aeterna Zentaris

Aeterna Zentaris is an oncology and endocrinology drug development company
currently investigating treatments for various unmet medical needs. The
Company's pipeline encompasses compounds at all stages of development, from
drug discovery through to marketed products. For more information please visit

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the
safe harbour provisions of the U.S. Securities Litigation Reform Act of 1995.
Forward-looking statements involve known and unknown risks and uncertainties
that could cause the Company's actual results to differ materially from those
in the forward-looking statements. For example, because the market price of
the Company's Common Shares will also be based on the Company's financial and
operational results, its financial position, including its capital
availabilities and liquidity resources, the development of its product
pipeline, market conditions, the market perception of its business and other
factors, which are unrelated to the number of shares outstanding, there can be
no assurance that the market price of the Common Shares will in fact increase
following the Consolidation or will not decrease in the future, or that the
minimum closing bid price of the Common Shares will meet NASDAQ's minimum bid
price requirement. Further, there can be no assurance that the Consolidation
alone will guarantee the continued listing of the Common Shares on The NASDAQ
Global Market or that the Common Shares will not be delisted due to a failure
to meet other NASDAQ continued listing requirements. Other such risks and
uncertainties include, among others, the availability of funds and resources
to pursue R&D projects, the successful and timely completion of clinical
studies, the risk that safety and efficacy data from any of our Phase 3 trials
may not coincide with the data analyses from previously reported Phase 1
and/or Phase 2 clinical trials, the ability of the Company to take advantage
of business opportunities in the pharmaceutical industry, uncertainties
related to the regulatory process and general changes in economic conditions.
Investors should consult the Company's quarterly and annual filings with the
Canadian and U.S. securities commissions for additional information on risks
and uncertainties relating to forward-looking statements. Investors are
cautioned not to rely on these forward-looking statements. The Company does
not undertake to update these forward-looking statements. We disclaim any
obligation to update any such factors or to publicly announce the result of
any revisions to any of the forward-looking statements contained herein to
reflect future results, events or developments, unless required to do so by a
governmental authority or by applicable law.



Investor Relations
Ginette Beaudet Vallières
Investor Relations Coordinator
(418) 652-8525 ext. 265

Media Relations
Paul Burroughs
Director of Communications
(418) 652-8525 ext. 406
Press spacebar to pause and continue. Press esc to stop.